A population-based study combining (i) antimicrobial, (ii) genetic, and (iii) virulence analyses with molecular evolutionary analyses revealed segregative characteristics distinguishing human clinical and bovine Escherichia coli O157 strains from western Canada. Human (n ‫؍‬ 50) and bovine (n ‫؍‬ 50) strains of E. coli O157 were collected from Saskatchewan and Manitoba in 2006 and were analyzed by using the six-marker lineage-specific polymorphism assay (LSPA6), antimicrobial susceptibility analysis, the colicin assay, plasmid and virulence profiling including the eae, ehxA, espA, iha, stx 1 , stx 2 , stx 2c , stx 2d , stx 2d-activatable , stx 2e , and stx 2f virulence-associated genes, and structure analyses. Multivariate logistic regression and Fisher's exact test strongly suggested that antimicrobial susceptibility was the most distinctive characteristic (P ‫؍‬ 0.00487) associated with human strains. Among all genetic, virulence, and antimicrobial determinants, resistance to tetracycline (P < 0.000) and to sulfisoxazole (P < 0.009) were the most strongly associated segregative characteristics of bovine E. coli O157 strains. Among 11 virulence-associated genes, stx 2c showed the strongest association with E. coli O157 strains of bovine origin. LSPA6 genotyping showed the dominance of the lineage I genotype among clinical (90%) and bovine (70%) strains, indicating the importance of lineage I in O157 epidemiology and ecology. Population structure analysis revealed that the more-diverse bovine strains came from a unique group of strains characterized by a high degree of antimicrobial resistance and high frequencies of lineage II genotypes and stx 2c variants. These findings imply that antimicrobial resistance generated among bovine strains of E. coli O157 has a large impact on the population of this human pathogen.
S
ince the discovery of Escherichia coli O157:H7 as the etiologic agent of hemorrhagic colitis in 1982 (1, 2) , the clinical importance of O157 has grown rapidly. For example, the Public Health Agency of Canada reported that the majority (95%) of human cases of E. coli-related illnesses in 1995 involved serovar O157 (3) . While the frequency of human illness due to E. coli O157 isolates has fallen in some regions of Canada (4), O157 remains a significant concern due to its demonstrated ability to cause both sporadic and large outbreaks. In July 1996, the city of Sakai, Japan, experienced the largest outbreak of O157 ever recorded, which was part of a series of outbreaks that summer that caused an estimated 8,000 cases and 6 deaths (5). The most potent virulence features of E. coli O157:H7 are the Shiga toxins (Stx1 and Stx2), a family of unique heterodimeric protein toxins (6) that are responsible for a wide spectrum of clinical symptoms, including lifethreatening complications such as hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura (7, 8) .
The ruminant gastrointestinal tract is the primary reservoir of E. coli O157 (9, 10) and the presence of this human pathogen in nature, in either water or soil, is derived from the primary habitat, usually by fecal contamination. Human infection with E. coli O157:H7 has been associated with various transmission routes, including direct exposure to infected animals (11, 12) , person-to-person passage (13) , and, primarily, consumption of contaminated foods and water (14, 15) . From the public health perspective, it is important to gain insight into the molecular epidemiology of Shiga toxin-producing E. coli (STEC) O157 isolates, which pose a high risk to humans. An increasing number of studies (16) (17) (18) indicate the existence of certain lineages of E. coli O157 that are more closely associated with human diseases than are others, and these studies further point to apparent differences in virulence and host ecology within the STEC O157 population. For instance, Ziebell et al. (19) applied the six-marker lineage-specific polymorphism assay (LSPA6), which is based on six selectively neutral markers (20) , to populations of E. coli O157 from Canada and found that most E. coli O157:H7 strains isolated from cattle and humans in Canada (82.6%) belonged to lineage I. Recently, Franz et al. (16) , performing a similar study with E. coli O157 isolates from the Netherlands, found a distinct fraction of STEC O157 strains in the bovine reservoir being associated with disease in humans. In contrast, human clinical E. coli O157 isolates originating from the Netherlands had a low frequency of LSPA6 lineage I strains and a high frequency of LSPA6 lineage I/II strains, indicating different epidemiological features for E. coli O157 isolates from Canada and the Netherlands. Together with the genetic and virulence differences, it is important to examine the antimicrobial resistance of these two groups of pathogens, as the emergence of antimicrobial resistance plays an important role in the epidemiology of pathogens of public health concern.
The present study genetically and phenotypically characterized and compared two pathogen populations, i.e., bovine and human clinical E. coli O157 strains (n ϭ 100), that were isolated from the sessed all of the aforementioned virulence determinants. Pseudomonas fluorescens strain cc840406E was used as a negative control. PCRs were carried out in 50-l reaction volumes, using an Eppendorf Mastercycler thermocycler (Eppendorf AG; Brinkman Instruments, Westbury, NY).
Antibiotic susceptibility testing. Escherichia coli O157 strains obtained from both bovine and human sources were examined for antibiotic resistance determinants using Sensititre CMV1AGNF plates (TREK Diagnostic Systems, Cleveland, OH). The Sensititre plates each contained 17 antimicrobial agents, i.e., amikacin (0.5 to 32 g/ml), ampicillin (1 to 64 g/ml), amoxicillin-clavulanic acid (1/0.5 to 32/16 g/ml), ceftriaxone (0.25 to 64 g/ml), ciprofloxacin (0.015 to 4 g/ml), cefoxitin (0.5 to 32 g/ml), gentamicin (0.25 to 16 g/ml), kanamycin (8 to 64 g/ml), nalidixic acid (0.5 to 32 g/ml), trimethoprim-sulfamethoxazole (0.12/2.38 to 4/76 g/ml), ceftiofur (0.12 to 8 g/ml), sulfisoxazole (16 to 256 g/ ml), streptomycin (32 to 64 g/ml), tetracycline (4 to 32 g/ml), and chloramphenicol (2 to 32 g/ml), dosed in 96 wells at appropriate dilutions, as specified by the National Antimicrobial Resistance Monitoring System of the CDC. Each well of the Sensititre microtiter plate was inoculated according to the instructions of the manufacturer, followed by incubation at 37°C for 24 h. The MIC was manually determined for each isolate as being the lowest concentration of each antibiotic that inhibited visible growth. The MIC breakpoints were determined according to National Committee for Clinical Laboratory Standards performance standards M100-S12 (24) and M31-A2 (25) .
Plasmid profiling. Plasmid DNA was isolated as described elsewhere (26) . After extraction, the plasmid DNA was analyzed by electrophoresis (55 min at 100 W) on a 2% (wt/vol) agarose gel containing 0.125 g ml Ϫ1 ethidium bromide. A 1-kb DNA extension ladder (Invitrogen, Burlington, Canada) was used as a molecular weight marker. The bands were visualized under UV light and photographed using Alpha Imager software.
Assay for colicin production. Colicin production by the E. coli O157 strains was determined using the method of Pugsley and Oudega (27) . Briefly, a loopful of inoculum of freshly prepared E. coli O157 culture was placed on a circle (r ϭ 1 cm) of a freshly prepared lawn of E. coli C600 indicator organism grown on a Trypticase soy agar plate. After 24 h of incubation at 37°C, the strains were examined for zones of clearing surrounding the spots of E. coli O157 inoculation. Colicin-positive E. coli O157 strains resulted in a clear zone around the point of inoculation due to colicin inhibition of the indicator organism's growth, whereas colicindeficient E. coli O157 strains showed no zones of clearing. In this assay, E. coli O157:H7 strain EDL933 was used as a colicin-positive control, whereas E. coli DH5␣ was used as a negative control.
Population structure analysis. The program Structure (28) was used to investigate the population structure of E. coli O157 strains, using six loci from the LSPA6 assay (i.e., folD, Z5935, yhcG, rtcB, rbsB, and arp-iclR), 11 virulence-associated genes (i.e., eae, ehxA, espA, iha, stx 1 , stx 2 , stx 2c , stx 2d , stx 2d-activatable , stx 2e , and stx 2f ), and antimicrobial resistance phenotypes. A Bayesian model approach was used to infer population structure (K) within the studied collection of E. coli O157 strains and to assign strains individually to the best-fitting population. K values were evaluated by a Markov chain Monte Carlo algorithm with a 10-model run. Each of the 10 runs consisted of 10,000 burn-in steps, followed by 100,000 iterations using the admixture model. The programs CLUMPP (29) and DISTRUCT (30) were used to generate the initial graphs depicting the genetic, virulence, and antimicrobial resistance phenotype distributions across the clinical and bovine strains of E. coli O157.
Statistical analysis. In order to determine statistically significant differences in the proportions of genes and phenotypes for the human and bovine strains, we used Fisher's exact test (31) . With the Bonferroni correction for multiple comparisons, we considered P values of Յ0.05/m statistically significant (m is the total number of members for a given family). Here, our study focuses mainly on three families, LSPA6 (m ϭ 6), virulence factor (m ϭ 11), and antibiotic susceptibility (m ϭ 7). Also, a multivariate logistic regression model was used to illustrate the associa-tions between the genetic, virulence, and antimicrobial resistance variables and the origins of STEC O157. We implemented both Fisher's exact test and the logistic regression model in R (32).
RESULTS
Lineage-specific polymorphism assay. The majority (80%) of E. coli O157 isolates were typed as LSPA6 lineage I, followed by lineage II (15%) and lineage I/II (5%) ( Table 1) . Multivariate logistic regression analysis indicated that no significant (P Ͼ 0.0083) association existed between different LSPA6 genotypes and the origins of the strains. However, there was a significant difference (P Ͻ 0.006) in E. coli O157 LSPA6 genotype distributions for the clinical and bovine isolates. The most common human diseaseassociated genotype was LSPA6 lineage I (90%), followed by LSPA6 lineage I/II (6%) and LSPA6 lineage II (4%). Among the bovine E. coli O157 strains, LSPA6 lineage I was found at 70% frequency, whereas LSPA6 lineages II and I/II were detected with frequencies of 26% and 4%, respectively. The most significant human disease-associated alleles were LSPA6 lineage I rtcB (P Ͻ 0.000) and arp (P Ͻ 0.000), being found in 100% of the clinical E. coli O157 isolates. Three other alleles, i.e., LSPA6 lineage I Z5935, yhcG, and rbsB, also showed significant association (98%; P Ͻ 0.002) with human E. coli O157 strains. The folD allele showed a nonsignificant frequency (92%; P Ͻ 0.017) within this group of E. coli O157 strains. LSPA6 lineage I alleles also showed high frequencies among the bovine strains, ranging from 84% for rtcB to 76% for Z5935 and rbsB.
The bovine E. coli O157 strains showed a higher degree of diversity than the clinical E. coli O157 strains. Besides LSPA6 lineages I and I/II, the bovine strains possessed six genotypes within lineage II, including LSPA6 222121, 222122, 111112, 222222, 221222, and 221221, whereas the clinical strains had two LSPA6 genotypes, 112111 and 231121, within lineage II.
Virulence gene profiling. The distribution of 11 virulenceassociated genes, including eae, ehxA, espA, iha, stx 1 , stx 2 , stx 2c , stx 2d , stx 2d-activatable , stx 2e , and stx 2f , among the 100 E. coli O157 strains is shown in Table 2 . All E. coli O157 strains contained the stx 2e gene. All bovine strains and virtually all (98%) clinical strains were positive for the attachment-effacement gene (eae) and the enterohemolysin A gene (ehxA). A similar pattern of distribution was observed for the homologue adhesion gene (iha) and the Shiga toxin gene stx 2 , with all bovine strains and the great majority (96%) of clinical strains being positive for both of these genes. The stx 1 gene was found in 86% of the bovine strains and 78% of the clinical strains; however, this difference was not significant (P ϭ 0.43). A variant of the stx 2 gene, stx 2f , had a much lower frequency of occurrence in both the bovine (34%) and clinical (32%) strains than did either the stx 2 genes or the stx 1 genes. Most noteworthy is the finding that the distribution of the stx 2c gene showed the greatest difference (P ϭ 0.023) between the bovine (24%) and clinical (6%) strains. The secreted protein A gene (espA) was found in only two bovine strains. All of the strains were negative for stx 2d-activatable.
The most common combination of the various Shiga toxin genes in the examined collection of E. coli O157 isolates was the group with stx 2 and stx 2e , which accounted for 100% (n ϭ 50) of the bovine strains and 96% (n ϭ 48) of the clinical strains. The combination of three Shiga toxin genes, including stx 2 , stx 2e , and stx 2d , was another common feature seen in this collection, where it was shown to occur in 94% of both the bovine (n ϭ 47) and clinical (n ϭ 47) strains. Another common combination, involving four Shiga toxin variant genes, was the combination of stx 1 , stx 2 , stx 2d , and stx 2e , which was present in 76% (n ϭ 38) of the clinical strains and 74% (n ϭ 37) of the bovine strains. One clinical strain, which was isolated in Winnipeg, possessed only two Shiga toxin genes, stx 2e and stx 2f , of the 11 virulence genes tested.
Antibiotic susceptibility testing. The antibiotic resistance patterns of the bovine (n ϭ 50) and clinical (n ϭ 50) strains of E. coli O157 are shown in Table 3 . Approximately one-half of the E. coli O157 strains (54%; n ϭ 54) were resistant to at least one antibiotic, whereas 46% (n ϭ 46) of the strains were susceptible to all 17 antibiotics tested. Resistance was observed for sulfisoxazole, gentamicin, chloramphenicol, tetracycline, ampicillin, streptomycin, and cefoxitin. Multivariate logistic regression analysis revealed a significant (P ϭ 0.00487) association of the antimicrobial resistance phenotypes with the origins of the strains. The clinical strains of E. coli O157 showed a higher rate of susceptibility (62%); of 50 strains, 31 were susceptible to all tested antibiotics, compared with the bovine strains (30%), of which 15 strains showed susceptibility to the same set of antibiotics. The most profound difference between the clinical and bovine strains was observed for 33 (33) 16 (32) 17 (34) 1.000
the antibiotic tetracycline (P ϭ 0.000), with 36% of the bovine strains showing resistance to this antibiotic but only 4% of the clinical strains being resistant. Also, strong differences between the clinical and bovine strains were found for sulfisoxazole (P ϭ 0.009) and streptomycin (P ϭ 0.01).
One pattern of multidrug resistance, involving tetracycline, streptomycin, and sulfisoxazole, was observed for both clinical (2%) and bovine (10%) strains. Another two patterns of multidrug resistance, including (i) tetracycline, ampicillin, and streptomycin and (ii) chloramphenicol, tetracycline, streptomycin, and sulfisoxazole, were observed for clinical (2%) and bovine (6%) strains, respectively.
Plasmid profiling. The entire collection of clinical and bovine strains had eight different plasmid profiles. The great majority (99%) of E. coli O157 strains carried multiple plasmids, whereas only one clinical isolate harbored a single small plasmid (ϳ15 kb). There was no significant difference (P ϭ 0.1) between the plasmid profiles of the clinical strains and the bovine strains. The most frequent plasmid profile, consisting of pO157 and a small plasmid (ϳ15 kb), was found in 36 (72%) of the clinical strains and 43 (86%) of the bovine strains. Another four multiple-plasmid profiles were found in seven bovine and nine clinical strains and involved pO157 and the small ϳ15-kb plasmid in combination with one of the 20-kb, 35-kb, 40-kb, or 72-kb plasmids. Two more multiple-plasmid profiles, each involving four plasmids, were found in four clinical strains.
Colicin assay. In total, 16 strains (16%) were found to produce colicin. Colicin production was observed in six clinical strains (12%) and 10 bovine strains (20%). The majority of colicinogenic strains (87.5%) were observed among LSPA6 lineage I, whereas one strain (6.25%) showing the colicinogenic phenotype was found within LSPA6 lineage II and another strain (6.25%) with the same phenotype was found within LSPA6 lineage I/II. No significant difference was found between the frequencies of clinical and bovine colicinogenic strains.
Population structure analysis. The program Structure, which is based on estimated logarithmic probabilities, strongly suggested that the studied collection of E. coli O157 strains is composed of three distinct populations (K ϭ 3) (Fig. 1) . Furthermore, this assumption is confirmed by the fact that the majority of E. coli O157 strains were assigned to one of the three existing populations, creating asymmetric groups, which is a strong indication of the real population structure. The most notable observation on the studied collection of E. coli O157 isolates was that significant associations (88%; P ϭ 0.005) existed between the human strains and population A and/or B (Fig. 2) , whereas the strains of bovine origin did not show significant association with any specific population. Rather, the bovine isolates were equally distributed among the three populations (population A, 32.7%; population B, 32.8%; population C, 34.5%) (Fig. 2) . The means of the pairwise 
DISCUSSION
The present population-based study examined the (i) antimicrobial, (ii) genetic, and (iii) virulence profiles of a geographically and temporally well-defined collection of E. coli O157 isolates and revealed that antimicrobial susceptibility was the most distinctive feature (P ϭ 0.00487) distinguishing clinical strains from bovine strains. Both the multivariate logistic regression analysis and Fisher's exact test strongly suggested that, among all of the tested antimicrobial, genetic, and virulence variables, resistance to tetracycline (P Ͻ 0.000) and resistance to sulfisoxazole (P Ͻ 0.009) were the characteristics most strongly associated with the bovine strains of E. coli O157. In contrast to the bovine strains, these antimicrobial phenotypes occurred at low frequencies among the human E. coli O157 strains. These statistically significant differences between the bovine and human strains of E. coli O157 most likely can be explained by the mass application of antimicrobial growth promoters (AGPs), including oxytetracycline and chlortetracycline, in intensively managed cattle populations in North America (33, 34) . Exposure of the bovine strains of E. coli O157 to a constant selective pressure imposed by AGPs may result in the generation of antimicrobial resistance (35) that can be easily transmitted to other pathogens within the same population. We showed in our previous study (21) that the prevalence of this food-borne pathogen increased proportionally with cattle density, which further indicates that any emerging antimicrobial phenotype in these cattle population-dense environments can be easily disseminated throughout the population of E. coli O157 of bovine origin. In addition, O'Connor et al. (36) reported that the use of injectable oxytetracycline in cattle receiving in-feed chlortetracycline was associated with an increase in the prevalence of resistance to sulfisoxazole, another antimicrobial agent with resistance significantly associated with the bovine strains in the present study. The high prevalence of sulfisoxazole and streptomycin resistance among the bovine strains might be explained by profound effects of tetracycline on the transfer, mobilization, and transposition of mobile genetic elements that might contain a variety of antibiotic resistance gene cassettes (37) (38) (39) . It was shown that a Ͼ100-fold increase in gene transfer occurred among bacteria harboring transposons that were exposed to low concentrations of tetracycline (38, 39) . Our data support this explanation with the fact that the most common multidrug-resistant phenotype observed in the collection of E. coli O157 strains included resistance to tetracycline, sulfisoxazole, and streptomycin. This observation indicates that these two antibiotic-resistant phenotypes, involving sulfisoxazole and streptomycin, were most likely introduced into the bovine strains via tetracycline-induced transposition of a mobile DNA element that already contained all three resistant determinants. The high rate of antimicrobial susceptibility among the clinical strains of E. coli O157 was most likely associated with the absence of selective pressure within the population of this human pathogen. Another factor contributing to the increased antimicrobial susceptibility among the clinical E. coli O157 strains might be associated with the short-lived nature of tetracycline resistance (40) and spontaneous or stress-induced loss of mobile DNA elements that harbor multidrug resistance genes. A high level of transposon loss was noted when bacteria were exposed to UV light or other stress-inducing treatments (41, 42) . It might be assumed that clinical strains of E. coli O157, changing their natural habitat and entering into the human food chain, would be exposed to significant stress conditions for extended periods prior to human infection, which might result in rapid loss of the mobile DNA elements that harbor antibiotic resistance genes. Taken together, these results support the hypothesis that the mass application of AGPs to food animals housed in population-dense environments most likely has a significant effect on the emergence and dissemination of antimicrobial resistance phenotypes (34, 43) . During the past decade, population genetics-based studies have increasingly shaped our understanding of the diversity and complexity of E. coli O157 populations. Several studies using LSPA6 genotyping showed distinct geographically dependent distributions of E. coli O157 isolates with clinical and bovine origins (16, 17, 19, 20) . For instance, Yang et al. (20) , using a large collection of 1,429 human and bovine isolates from the United States and Australia, showed that lineage I was the LSPA6 genotype most frequently identified in both human and bovine isolates, including dairy herds and feedlots. Another study from Canada also pointed out that lineage I was the predominant LSPA6 genotype among human and bovine isolates (19) . A population-based study from Japan (17) revealed that lineages II and I/II were the most common LSPA6 genotypes among bovine isolates, whereas lineage I was the predominant (69.2%) LSPA6 genotype among human clinical isolates. Recently, Franz and colleagues (16) showed that the distributions of LSPA6 genotypes among human and bovine O157 isolates in the Netherlands were quite different from those in the United States, Australia, and Japan. The most notable differences were the low rate of occurrence of lineage I and the high rate of occurrence of lineage I/II in human isolates of E. coli O157 from the Netherlands. The present study showed a predominance of lineage I among human (90%) and bovine (70%) isolates from a vast area of western Canada and, together with the previously published studies (19, 20) , indicates the importance of lineage I in the ecology and epidemiology of E. coli O157 isolates from North America.
Evaluation of the E. coli O157 strains for 11 virulence-associated genes revealed that intimin, the enterohemorrhagic E. coli hemolysin, the IrgA homologue adhesin encoded by iha (44) , and the Shiga toxins encoded by stx 2 and a stx 2 variant were distributed virtually across all clinical and bovine strains, indicating the ubiquitous nature of these virulence-associated determinants regardless of the pathogen's origin. A study examining the population genetics of the Shiga toxin-producing E. coli (STEC) in Montana in the United States, targeting the same 11 virulence-associated genes, also showed the high prevalence of intimin (100%), enterohemorrhagic E. coli hemolysin (100%), IrgA homologue adhesin (100%), and stx 2 variant (91%) genes within the E. coli O157 population. Notably, these four virulence determinants were less frequent among non-O157 STEC strains, with occurrence rates ranging from 36% for the stx 2 variant to 88% for enterohemorrhagic E. coli hemolysin (22) , indicating a lower virulence potency of non-O157 STEC than of E. coli O157. In sharp contrast to these four virulence-associated genes, which were evenly distributed among the human and bovine strains, we found that the stx 2c Shiga toxin variant was the most segregative virulence determinant (P ϭ 0.02) and was associated with E. coli O157 strains of bovine origin. Our data imply that the association between the stx 2c variant and the bovine strains was due to a very strong correlation (93.3%) between lineage II and stx 2c . A majority of lineage II genotypes (86.7%) were identified among bovine strains, whereas only a small fraction (13.7%) of these LSPA6 genotypes were observed among clinical strains. Several other studies also reported a strong association between stx 2c and bovine isolates (16, 17, 19) .
Population structure analysis of human clinical and bovine O157 strains, obtained over the same period of time from a confined geographical region, confirmed the earlier hypothesis that bovine strains represent a more heterogeneous group of organisms than human clinical isolates (16, 17, 45, 46) . More importantly, we have shown that the greater diversity of bovine strains is attributable to a distinct population of pathogen that is rarely found among clinical strains (Fig. 1) . This unique population of E. coli O157 strains, termed population C, was the most heterogeneous pathogen group, as indicated by the mean of the pairwise distances, with unique antimicrobial, genetic, and virulence profiles. The most important characteristics of population C of E. coli O157 strains were a high degree of antimicrobial resistance, a relatively high prevalence of different LSPA6 genotypes of lineage II, and a high frequency of stx 2c variants. In contrast, the other two populations (populations A and B) encompassed a great majority of the human clinical strains (88%) and were characterized by a high frequency of antimicrobial susceptibility, a high prevalence of the lineage I genotype, and a common virulence profile that included a combination of stx 1 -positive and stx 2c -negative variants.
In summary, the present study, which tested a temporally and geographically well-defined population of E. coli O157 strains, clearly indicated that, among different antimicrobial, genetic, and virulence determinants, antimicrobial susceptibility was the most distinctive characteristic that distinguished human strains from bovine strains of E. coli O157 in the region of western Canada. Furthermore, this finding implies that the selective pressure that generates antimicrobial resistance (use of antimicrobials to promote animal growth) in intensively managed livestock operations has a large impact on the population of this human pathogen. In addition, by implementing a broad spectrum of antimicrobial, genetic, and virulence analyses in combination with molecular evolutionary analyses, we were able to identify a unique E. coli O157 group rarely found among clinical strains and commonly identified among bovine strains.
